In today’s session Novartis AG (ADR) (NVS) recorded an unusually high (588) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious NVS decrease. With 588 contracts traded and 20684 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: NVS161118P00070000 closed last at: $0.7 or 30% down. About 1.11M shares traded hands. Novartis AG (ADR) (NYSE:NVS) has declined 1.24% since April 8, 2016 and is downtrending. It has underperformed by 6.88% the S&P500.
Novartis AG (ADR) (NYSE:NVS) Ratings Coverage
Out of 9 analysts covering Novartis Ag (NYSE:NVS), 3 rate it a “Buy”, 2 “Sell”, while 4 “Hold”. This means 33% are positive. $110 is the highest target while $85 is the lowest. The $92.75 average target is 26.38% above today’s ($73.39) stock price. Novartis Ag has been the topic of 14 analyst reports since July 28, 2015 according to StockzIntelligence Inc. On Wednesday, October 28 the stock rating was downgraded by Mainfirst to “Underperform”. The firm earned “Neutral” rating on Friday, April 1 by UBS. The rating was initiated by Argus Research on Tuesday, April 5 with “Hold”. Argus Research upgraded Novartis AG (ADR) (NYSE:NVS) on Thursday, November 10 to “Buy” rating. The firm has “Neutral” rating given on Tuesday, March 29 by Citigroup. Morgan Stanley downgraded Novartis AG (ADR) (NYSE:NVS) on Tuesday, April 12 to “Underperform” rating. Chardan Capital Markets maintained the shares of NVS in a report on Monday, October 10 with “Buy” rating. Leerink Swann downgraded the stock to “Market Perform” rating in Wednesday, March 23 report. The firm earned “Buy” rating on Tuesday, September 20 by Chardan Capital Markets.
According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The company has a market cap of $200.50 billion. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. It has a 26.54 P/E ratio. The Company’s divisions include Pharmaceuticals, Alcon and Sandoz.
NVS Company Profile
Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.